-
1
-
-
0025243470
-
Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history
-
2253003 10.1002/bjs.1800771115 1:STN:280:DyaK3M%2FntVajsw%3D%3D
-
Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241-6.
-
(1990)
Br J Surg
, vol.77
, pp. 1241-1246
-
-
Scheele, J.1
Stangl, R.2
Altendorf-Hofmann, A.3
-
2
-
-
77953632852
-
Surgical management and outcomes of colorectal cancer liver metastases
-
10.1002/bjs.7032 20632280 10.1002/bjs.7032 1:STN:280: DC%2BC3cnnvFWmtw%3D%3D
-
Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010;97:1110-8. doi: 10.1002/bjs.7032.
-
(2010)
Br J Surg
, vol.97
, pp. 1110-1118
-
-
Morris, E.J.1
Forman, D.2
Thomas, J.D.3
Quirke, P.4
Taylor, E.F.5
Fairley, L.6
-
3
-
-
33645731843
-
Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies
-
10.1038/sj.bjc.6603033 16538219 10.1038/sj.bjc.6603033 1:STN:280:DC%2BD287pt1altw%3D%3D
-
Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-99. doi: 10.1038/sj.bjc.6603033.
-
(2006)
Br J Cancer
, vol.94
, pp. 982-999
-
-
Simmonds, P.C.1
Primrose, J.N.2
Colquitt, J.L.3
Garden, O.J.4
Poston, G.J.5
Rees, M.6
-
4
-
-
33645873301
-
Survival after hepatic resection for colorectal metastases: A 10-year experience
-
10.1245/ASO.2006.05.039 16523369 10.1245/ASO.2006.05.039
-
Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668-76. doi: 10.1245/ASO.2006.05.039.
-
(2006)
Ann Surg Oncol
, vol.13
, pp. 668-676
-
-
Wei, A.C.1
Greig, P.D.2
Grant, D.3
Taylor, B.4
Langer, B.5
Gallinger, S.6
-
5
-
-
33846939792
-
Survival after hepatic resection in metastatic colorectal cancer: A population-based study
-
10.1002/cncr.22448 17238180 10.1002/cncr.22448
-
Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109:718-26. doi: 10.1002/cncr.22448.
-
(2007)
Cancer
, vol.109
, pp. 718-726
-
-
Cummings, L.C.1
Payes, J.D.2
Cooper, G.S.3
-
6
-
-
34548476513
-
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
-
10.1016/j.ejca.2007.07.017 17766104 10.1016/j.ejca.2007.07.017 1:CAS:528:DC%2BD2sXhtVCitrzJ
-
Nordlinger B, Van Cutsem E, Rougier P, Kohne CH, Ychou M, Sobrero A, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007;43:2037-45. doi: 10.1016/j.ejca.2007.07.017.
-
(2007)
Eur J Cancer
, vol.43
, pp. 2037-2045
-
-
Nordlinger, B.1
Van Cutsem, E.2
Rougier, P.3
Kohne, C.H.4
Ychou, M.5
Sobrero, A.6
-
7
-
-
75449110555
-
Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis
-
10.1111/j.1477-2574.2009.00119.x 10.1111/j.1477-2574.2009.00119.x
-
Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford). 2010;12:37-42. doi: 10.1111/j.1477-2574. 2009.00119.x.
-
(2010)
HPB (Oxford)
, vol.12
, pp. 37-42
-
-
Chaudhury, P.1
Hassanain, M.2
Bouganim, N.3
Salman, A.4
Kavan, P.5
Metrakos, P.6
-
8
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
10.1056/NEJMoa032691 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. doi: 10.1056/NEJMoa032691.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
9
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
10.1200/JCO.2010.33.5091 21502544 10.1200/JCO.2010.33.5091
-
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-9. doi: 10.1200/JCO.2010.33.5091.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Kohne, C.H.2
Lang, I.3
Folprecht, G.4
Nowacki, M.P.5
Cascinu, S.6
-
10
-
-
33845961014
-
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
-
10.1016/j.clinthera.2006.11.015 17212999 10.1016/j.clinthera.2006.11.015 1:CAS:528:DC%2BD2sXhtVClsbg%3D
-
Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779-802. doi: 10.1016/j.clinthera.2006.11.015.
-
(2006)
Clin Ther
, vol.28
, pp. 1779-1802
-
-
Shih, T.1
Lindley, C.2
-
11
-
-
81855197110
-
A systematic review of treatment guidelines for metastatic colorectal cancer
-
10.1111/j.1463-1318.2011.02765.x 21848897 10.1111/j.1463-1318.2011.02765. x 1:STN:280:DC%2BC387jt12jsQ%3D%3D
-
Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012;14:e31-47. doi: 10.1111/j.1463-1318.2011.02765.x.
-
(2012)
Colorectal Dis
, vol.14
-
-
Edwards, M.S.1
Chadda, S.D.2
Zhao, Z.3
Barber, B.L.4
Sykes, D.P.5
-
12
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
13
-
-
63049105306
-
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
-
10.1016/j.ejso.2008.12.013 19200687 10.1016/j.ejso.2008.12.013 1:STN:280:DC%2BD1M3ltlyrtg%3D%3D
-
Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35:515-20. doi: 10.1016/j.ejso.2008.12.013.
-
(2009)
Eur J Surg Oncol
, vol.35
, pp. 515-520
-
-
Klinger, M.1
Eipeldauer, S.2
Hacker, S.3
Herberger, B.4
Tamandl, D.5
Dorfmeister, M.6
-
14
-
-
67349207407
-
Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy
-
10.1016/j.ctrv.2008.12.001 19136215 10.1016/j.ctrv.2008.12.001 1:CAS:528:DC%2BD1MXmtlOqtr4%3D
-
Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35:309-21. doi: 10.1016/j.ctrv.2008.12.001.
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 309-321
-
-
Desar, I.M.1
Van Herpen, C.M.2
Van Laarhoven, H.W.3
Barentsz, J.O.4
Oyen, W.J.5
Van Der Graaf, W.T.6
-
15
-
-
84867495878
-
RECIST: No longer the sharpest tool in the oncology clinical trials toolbox - Point
-
10.1158/0008-5472.CAN-12-0058 22952219 10.1158/0008-5472.CAN-12-0058 1:CAS:528:DC%2BC38XhsFWrsrjE
-
Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox - point. Cancer Res. 2012;72:5145-9. doi: 10.1158/0008-5472.CAN-12-0058.
-
(2012)
Cancer Res
, vol.72
, pp. 5145-5149
-
-
Sharma, M.R.1
Maitland, M.L.2
Ratain, M.J.3
-
16
-
-
79851482347
-
Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI
-
10.2967/jnumed.110.078261 21149474 10.2967/jnumed.110.078261
-
de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;52:48-55. doi: 10.2967/jnumed.110. 078261.
-
(2011)
J Nucl Med
, vol.52
, pp. 48-55
-
-
De Langen, A.J.1
Van Den Boogaart, V.2
Lubberink, M.3
Backes, W.H.4
Marcus, J.T.5
Van Tinteren, H.6
-
17
-
-
66149096269
-
Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review
-
10.2967/jnumed.108.057224 19403879 10.2967/jnumed.108.057224
-
de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009;50 Suppl 1:43S-54S. doi: 10.2967/jnumed.108.057224.
-
(2009)
J Nucl Med
, vol.50
, Issue.SUPPL. 1
-
-
De Geus-Oei, L.F.1
Vriens, D.2
Van Laarhoven, H.W.3
Van Der Graaf, W.T.4
Oyen, W.J.5
-
18
-
-
70350707775
-
Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate
-
10.2967/jnumed.109.064790 19837750 10.2967/jnumed.109.064790 1:CAS:528:DC%2BD1MXhsVyqs73P
-
Vriens D, van Laarhoven HW, van Asten JJ, Krabbe PF, Visser EP, Heerschap A, et al. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J Nucl Med. 2009;50:1777-84. doi: 10.2967/jnumed.109.064790.
-
(2009)
J Nucl Med
, vol.50
, pp. 1777-1784
-
-
Vriens, D.1
Van Laarhoven, H.W.2
Van Asten, J.J.3
Krabbe, P.F.4
Visser, E.P.5
Heerschap, A.6
-
19
-
-
84864312702
-
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
-
10.1093/annonc/mdr554 22112970 10.1093/annonc/mdr554 1:STN:280: DC%2BC38znvFaitA%3D%3D
-
Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012;23:1687-93. doi: 10.1093/annonc/mdr554.
-
(2012)
Ann Oncol
, vol.23
, pp. 1687-1693
-
-
Hendlisz, A.1
Golfinopoulos, V.2
Garcia, C.3
Covas, A.4
Emonts, P.5
Ameye, L.6
-
20
-
-
84868211531
-
The age of reason for FDG PET image-derived indices
-
10.1007/s00259-012-2239-0 22968400 10.1007/s00259-012-2239-0
-
Visvikis D, Hatt M, Tixier F, Cheze Le Rest C. The age of reason for FDG PET image-derived indices. Eur J Nucl Med Mol Imaging. 2012;39:1670-2. doi: 10.1007/s00259-012-2239-0.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 1670-1672
-
-
Visvikis, D.1
Hatt, M.2
Tixier, F.3
Cheze Le Rest, C.4
-
21
-
-
66149139452
-
From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors
-
19403881 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D
-
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50S.
-
(2009)
J Nucl Med
, vol.50
, Issue.SUPPL. 1
-
-
Wahl, R.L.1
Jacene, H.2
Kasamon, Y.3
Lodge, M.A.4
-
22
-
-
6944235697
-
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study
-
15347719
-
Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519-27.
-
(2004)
J Nucl Med
, vol.45
, pp. 1519-1527
-
-
Boellaard, R.1
Krak, N.C.2
Hoekstra, O.S.3
Lammertsma, A.A.4
-
23
-
-
0000827344
-
Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis
-
14516540 10.1016/S1095-0397(99)00016-3
-
Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-71.
-
(1999)
Clin Positron Imaging
, vol.2
, pp. 159-171
-
-
Larson, S.M.1
Erdi, Y.2
Akhurst, T.3
Mazumdar, M.4
Macapinlac, H.A.5
Finn, R.D.6
-
24
-
-
84865622726
-
Standardized added metabolic activity (SAM): A partial volume independent marker of total lesion glycolysis in liver metastases
-
10.1007/s00259-012-2166-0 22699529 10.1007/s00259-012-2166-0 1:CAS:528:DC%2BC38XhtFKis7jF
-
Mertens J, Dobbeleir A, Ham H, D'Asseler Y, Goethals I, Van de Wiele C. Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. Eur J Nucl Med Mol Imaging. 2012;39:1441-8. doi: 10.1007/s00259-012-2166-0.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 1441-1448
-
-
Mertens, J.1
Dobbeleir, A.2
Ham, H.3
D'Asseler, Y.4
Goethals, I.5
Van De Wiele, C.6
-
25
-
-
84891671878
-
Comment on Mertens et al.: Standardized added metabolic activity (SAM): A partial volume independent marker of total lesion glycolysis in liver metastases
-
10.1007/s00259-013-2364-4 23436071 10.1007/s00259-013-2364-4
-
Fleming JS, Tossici-Bolt L, Guy M, Kemp P. Comment on Mertens et al.: standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. Eur J Nucl Med Mol Imaging. 2013;40:788-9. doi: 10.1007/s00259-013-2364-4.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 788-789
-
-
Fleming, J.S.1
Tossici-Bolt, L.2
Guy, M.3
Kemp, P.4
-
26
-
-
4344713082
-
The specific uptake size index for quantifying radiopharmaceutical uptake
-
15357202 10.1088/0031-9155/49/14/N03 1:CAS:528:DC%2BD2cXntVeluro%3D
-
Fleming JS, Bolt L, Stratford JS, Kemp PM. The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol. 2004;49:N227-34.
-
(2004)
Phys Med Biol
, vol.49
-
-
Fleming, J.S.1
Bolt, L.2
Stratford, J.S.3
Kemp, P.M.4
-
27
-
-
57849110449
-
Individual patient data analysis to assess modifications to the RECIST criteria
-
19095437 10.1016/j.ejca.2008.10.027
-
Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009;45:248-60.
-
(2009)
Eur J Cancer
, vol.45
, pp. 248-260
-
-
Bogaerts, J.1
Ford, R.2
Sargent, D.3
Schwartz, L.H.4
Rubinstein, L.5
Lacombe, D.6
-
28
-
-
84869093139
-
Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer
-
10.1007/s00259-012-2233-6 22945372 10.1007/s00259-012-2233-6 1:CAS:528:DC%2BC38Xhs1GqsLfL
-
Heijmen L, de Geus-Oei LF, de Wilt JH, Visvikis D, Hatt M, Visser EP, et al. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging. 2012;39:1858-67. doi: 10.1007/s00259-012-2233-6.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 1858-1867
-
-
Heijmen, L.1
De Geus-Oei, L.F.2
De Wilt, J.H.3
Visvikis, D.4
Hatt, M.5
Visser, E.P.6
-
29
-
-
66149111586
-
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
-
10.1093/annonc/mdn744 19164458 10.1093/annonc/mdn744 1:STN:280: DC%2BD1MzmtlGhtg%3D%3D
-
Bystrom P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol. 2009;20:1057-61. doi: 10.1093/annonc/mdn744.
-
(2009)
Ann Oncol
, vol.20
, pp. 1057-1061
-
-
Bystrom, P.1
Berglund, A.2
Garske, U.3
Jacobsson, H.4
Sundin, A.5
Nygren, P.6
-
30
-
-
34250625327
-
18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases
-
10.2967/jnumed.106.037291 17475966 10.2967/jnumed.106.037291
-
Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771-5. doi: 10.2967/jnumed.106.037291.
-
(2007)
J Nucl Med
, vol.48
, pp. 771-775
-
-
Riedl, C.C.1
Akhurst, T.2
Larson, S.3
Stanziale, S.F.4
Tuorto, S.5
Bhargava, A.6
-
31
-
-
13944279944
-
Monitoring response to treatment in patients utilizing PET
-
15693656 10.1016/j.rcl.2004.09.006
-
Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189-204.
-
(2005)
Radiol Clin North Am
, vol.43
, pp. 189-204
-
-
Avril, N.E.1
Weber, W.A.2
-
32
-
-
6944222538
-
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy
-
15347714 1:CAS:528:DC%2BD2cXosVWis7o%3D
-
Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruhl A, Irngartinger G, Stremmel W, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480-7.
-
(2004)
J Nucl Med
, vol.45
, pp. 1480-1487
-
-
Dimitrakopoulou-Strauss, A.1
Strauss, L.G.2
Burger, C.3
Ruhl, A.4
Irngartinger, G.5
Stremmel, W.6
-
33
-
-
38849118300
-
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer
-
17962202 10.1093/annonc/mdm470
-
de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348-52.
-
(2008)
Ann Oncol
, vol.19
, pp. 348-352
-
-
De Geus-Oei, L.F.1
Van Laarhoven, H.W.2
Visser, E.P.3
Hermsen, R.4
Van Hoorn, B.A.5
Kamm, Y.J.6
-
34
-
-
0038354700
-
PET-FDG as predictor of therapy response in patients with colorectal carcinoma
-
12714949 1:STN:280:DC%2BD3s7psFGhug%3D%3D
-
Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med. 2003;47:8-13.
-
(2003)
Q J Nucl Med
, vol.47
, pp. 8-13
-
-
Dimitrakopoulou-Strauss, A.1
Strauss, L.G.2
Rudi, J.3
-
35
-
-
33947596928
-
Monitoring cancer treatment with PET/CT: Does it make a difference?
-
17204719 1:CAS:528:DC%2BD2sXitVanu7c%3D
-
Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med. 2007;48 Suppl 1:36S-44S.
-
(2007)
J Nucl Med
, vol.48
, Issue.SUPPL. 1
-
-
Weber, W.A.1
Figlin, R.2
-
36
-
-
79953719364
-
PET functional volume delineation: A robustness and repeatability study
-
10.1007/s00259-010-1688-6 21225425 10.1007/s00259-010-1688-6
-
Hatt M, Cheze Le Rest C, Albarghach N, Pradier O, Visvikis D. PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging. 2011;38:663-72. doi: 10.1007/s00259-010-1688-6.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 663-672
-
-
Hatt, M.1
Cheze Le Rest, C.2
Albarghach, N.3
Pradier, O.4
Visvikis, D.5
|